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AlgX is a periplasmic protein required for the production of the exopoly-
saccharide alginate in Pseudomonas sp. and Azotobacter vinelandii. AlgX has
been overexpressed and purified and diffraction-quality crystals have been
grown using iterative seeding and the hanging-drop vapor-diffusion method.
The crystals grew as flat plates with unit-cell parameters a = 46.4, b = 120.6,
c = 86.9 A˚, = 95.7. The crystals exhibited the symmetry of space group P21 and
diffracted to a minimum d-spacing of 2.1 A˚. On the basis of the Matthews
coefficient (VM = 2.25 A˚
3 Da1), two molecules were estimated to be present in
the asymmetric unit.
1. Introduction
The later stages of cystic fibrosis (CF) disease are characterized by
chronic respiratory infections caused by the opportunistic pathogen
Pseudomonas aeruginosa. The establishment of these infections is an
indicator of poor prognoses (Govan & Deretic, 1996) and P. aeru
ginosa infections remain the leading cause of death and morbidity in
CF patients (Leid et al., 2005). Treatment of the chronic infections is
ineffective owing to the intrinsic resistance of the bacteria (Hancock,
1998; Pier et al., 2001), which arises at least in part from the
conversion of the bacteria from a nonmucoid to a mucoid phenotype
(Koch & Høiby, 2000; Conway et al., 2003). The mucoid phenotype is
characterized by the production of large quantities of the exopoly
saccharide alginate.
Alginate is synthesized as a linear polymer of  1,4 linked
d mannuronic acid from the activated sugar nucleotide precursor
GDP mannuronic acid (Evans & Linker, 1973). Polymerization is
believed to occur on the cytoplasmic face of the inner membrane and
appears to require not only Alg8, a putative CAZy (carbohydrate
active enzymes) family 2 glycosyltransferase (Maharaj et al., 1993;
Oglesby et al., 2008; Remminghorst & Rehm, 2006a), but also the bis
(30,50) cyclic GMP binding PilZ domain containing Alg44 (Maharaj
et al., 1993; Merighi et al., 2007; Oglesby et al., 2008; Remminghorst &
Rehm, 2006b). The exact mechanism by which the growing homo
polymer is exported across the inner membrane into the periplasm
is not known but is thought to involve the transmembrane spanning
domains of Alg8. In the periplasm the d mannuronate residues can
be either epimerized to  l guluronic acid by AlgG (Franklin et al.,
1994), selectively acetylated at the O20 and/or O30 hydroxyls by the
concerted action of AlgI, AlgJ and AlgF (Franklin & Ohman, 2002)
or remain unaltered (Jain & Ohman, 2004). As the modified alginate
polymer traverses the periplasm, its proper export is dependent upon
the remaining proteins of the putative alginate biosynthetic complex:
AlgK, AlgE, AlgL and AlgX (Jain & Ohman, 2004, 2005; Rehm et
al., 1994; Robles Price et al., 2004). The AlgK/E proteins have been
proposed to form the basis of a novel class of exopolysaccharide
secretin (Keiski et al., 2010). AlgE bears a resemblance to outer
membrane  barrel porins and has been proposed to form a pore that
allows the polymer to traverse the outer membrane (Hay et al., 2009;
Rehm et al., 1994; Whitney et al., 2009). Recent structural and func
tional characterization of AlgK has shown that this protein is
composed of at least 9.5 tetratricopeptide (TPR) protein protein
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interaction motifs and may form the scaffold for the assembly of the
periplasmic alginate biosynthetic complex. Indeed, AlgK has been
shown to facilitate the correct localization of AlgE (Keiski et al.,
2010) and may also be involved in the coordination of AlgL and
AlgX. AlgL appears to have a dual role involving both the degra
dation of alginate within the periplasm and as a protein within the
secretion complex (Jain & Ohman, 2005; Bakkevig et al., 2005), while
the exact role of AlgX is currently unknown (Robles Price et al., 2004;
Jain & Ohman, 1998).
The mature form of AlgX is a 49.9 kDa periplasmic protein
(Gutsche et al., 2006; Monday & Schiller, 1996). At the amino acid
level, the protein shares 31% and 69% sequence identity and simi
larity, respectively, to AlgJ, a protein that is required for alginate
acetylation (Franklin & Ohman, 1996, 2002). At the tertiary level,
the Phyre structure prediction server (Kelley & Sternberg, 2009)
suggests that the N terminal region of the protein, residues 50 200,
shares structural homology to members of the SGNH hydrolyase
superfamily of enzymes, which typically remove acyl groups from
carbohydrates and other compounds (Mølgaard et al., 2000; Lo et al.,
2003). The closest match is to an Enterococcus faecalis hydrolase
(PDB code 1yzf; R. Zhang, C. Hatzos, S. Clancy, F. Collart & A.
Joachimiak, unpublished work), which has 9% sequence identity to
AlgX over this region. At present no enzymatic activity has been
demonstrated for AlgX; while sequence analysis suggests that
Asp174 and His176 could form part of the signature Ser His Asp
catalytic triad of SGNH hydrolases, no candidate for the catalytic
serine can be readily identified. The C terminal region of the protein,
residues 201 474, shows no similarity to any protein of known
structure and there are no clearly conserved residues that would
define a putative function for this region of the protein. The identi
fication of an interaction between AlgX and MucD (Gutsche et al.,
2006), which is required for temperature resistance and alginate gene
regulation and is a close homologue of the Escherichia coli peri
plasmic serine protease HtrA (Wood & Ohman, 2006), further
complicates our understanding of the role that AlgX may play in
alginate production. Therefore, in order to obtain further insight into
the mechanism by which alginate is synthesized and exported and the
role of AlgX in this process we have undertaken structural studies of
AlgX and describe here the overexpression, purification and crys
tallization of the protein.
2. Materials and methods
2.1. Cloning and expression
The nucleotide sequence of algX from P. aeruginosa PAO1 was
codon optimized for expression in E. coli and the synthetic gene was
prepared by GenScript Corporation (Piscataway, New Jersey, USA).
Care was taken to ensure that the changes resulted only in silent
mutations of the coding sequence so that the expressed protein would
be identical at the amino acid level to P. aeruginosa PAO1 encoded
AlgX (GenBank/EMBL protein accession No. NP 252236; Winsor
et al., 2005). Unique restriction sites were chosen for the N and
C termini (NdeI and XhoI, respectively) to facilitate cloning of the
synthesized segment into the pET24b(+) vector (Novagen). This
construct (pPLHJTWX) facilitates the expression of the entire AlgX
protein including its signal sequence and a C terminal His6 tag under
the control of an isopropyl  d 1 thiogalactopyranoside (IPTG)
inducible promoter.
For the expression of high levels of protein, E. coli BL21 Codon
Plus (DE3) cells (Stratagene) transformed with the AlgX expression
vector pPLHJTWX were grown in 1 l rich medium (32 g tryptone,
20 g yeast extract, 5 g NaCl) containing 50 mg ml1 kanamycin at
310 K until the OD600 of the cell culture reached 0.6, at which point
protein expression was induced by the addition of IPTG to a final
concentration of 1 mM. After induction, the cells were incubated at
298 K for 16 h prior to being harvested by centrifugation at 5000g for
15 min at 277 K. The resulting cell pellet was stored at 253 K until
required.
2.2. Purification
To purify the AlgX His6 tagged protein, the cell pellet from 1 l of
bacterial culture was thawed and resuspended in 40 50 ml buffer A
[500 mM NaCl, 50 mM Tris HCl pH 7.8, 2%(v/v) glycerol, 2 mM
DTT] containing 1 mg ml1 lysozyme, 0.5 mM EDTA and one tablet
of Roche Complete protease inhibitor cocktail (EDTA free). This
suspension was incubated at 277 K for 30 min before being subjected
to lysis by sonication (Misonix Sonicator 3000) with cooling on ice for
3 min at power 5 (10 s on/10 s off) or until the lysate was translucent.
Unlysed cells were removed by centrifugation at 5000g for 15 min at
277 K. The supernatant was subsequently loaded onto a 5 ml Ni2+
NTA Superflow Cartridge (Qiagen) pre equilibrated with buffer A.
The column was washed with at least 15 column volumes of buffer A
to remove contaminating proteins. Bound protein was recovered
from the column using a gradient from 0 to 150 mM imidazole (in
buffer A) at a flow rate of 1 ml min1. The AlgX containing fractions,
which appeared at 75 90 mM imidazole, were pooled and concen
trated by centrifugation (2200g at 277 K) using a Millipore concen
trator with a 30 kDa molecular weight cutoff. The protein was
subsequently further purified and buffer exchanged into buffer B
[50 mM Tris HCl pH 7.8, 2%(v/v) glycerol, 2 mM DTT] by size
exclusion chromatography using a HiLoad 16/60 Superdex 200
prep grade gel filtration column (GE Healthcare). The purity of the
AlgX His6 protein was monitored at all stages of the purification
process using SDS PAGE (Fig. 1). The purified protein was analyzed
by MALDI TOF mass spectrometry at the Advanced Protein
Technology Centre at The Hospital for Sick Children and revealed a
single peak corresponding to the expected molecular weight of the
mature AlgX protein (i.e. minus its signal sequence but containing
the C terminal His6 tag). Following purification, samples could be
stored at 277 K for up to one week at concentrations below 4 mg ml1
without visible precipitation or loss of the ability to readily form
crystals.
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Figure 1
SDS–PAGE analysis of AlgX-His6 during expression and purification. Lane M,
molecular-weight markers (kDa); lane 1, whole cell lysate; lane 2, AlgX after Ni-
affinity chromatography; lane 3, AlgX after size-exclusion chromatography.
2.3. Crystallization
Preparations of purified protein at 4 and 8 mg ml1 were used for
the initial crystallization trials with ten different sparse matrix crystal
screens from Emerald BioSystems and Qiagen. These trials were set
up in 48 well VDX plates (Hampton Research) by hand with 2 ml
drops containing different ratios (1:1, 2:1 and 1:2) of protein solution
and mother liquor over a reservoir containing 0.2 ml mother liquor.
There were a number of hits from these trials, but the best looking
crystals always contained a low molecular weight polyethylene glycol
(PEG) as the precipitant. Extensive optimization was carried out on
condition No. 6 [100 mM sodium citrate pH 5.5, 20%(w/v) PEG 3000]
from the Wizard I random sparse matrix crystallization screen
(Emerald BioSystems) by setting up approximately 150 variations of
these conditions using the hanging drop vapour diffusion method in
24 well VDX plates (Hampton Research) with 4 ml drops containing
a 1:1 ratio of protein solution (3 mg ml1) and mother liquor over a
reservoir containing 0.5 ml mother liquor. This yielded single crystals
that were small in size (50 20 20 mm) and took up to two weeks to
grow at 293 K (Fig. 2a). Further optimization involved the use of at
least two successive rounds of seeding with seed beads and a streak
seeding tool (Hampton Research). Briefly, 4 8 crystals were
extracted from a drop using a pipette and resuspended in 50 ml
reservoir solution containing an additional 2 5%(w/v) PEG 3000.
These crystals were crushed by vortexing them for 30 s in the
presence of a seed bead and diluted by 20 50 fold. Streak seeding
from these diluted stocks was performed by dipping the streak
seeding tool into the diluted seed stock solution and then dragging it
once through prepared drops. This procedure yielded a variety of
crystals from 100 mM sodium citrate pH 5.2, 14 18%(w/v) PEG 3000
that took only a few days to grow to maximum dimensions of 200 
100  100 mm (Fig. 2b).
2.4. Data collection
In preparation for data collection, two different cryosolutions were
tested. The first consisted of adding glycerol directly to the reservoir
solution of the crystal to a final concentration of 25%(v/v). However,
the crystals fared much better in cryoprotectants that consisted of
exact concentrations of 100 mM sodium citrate pH 5.2, 0.5 mM DTT,
25%(v/v) glycerol and a PEG 3000 concentration that was 2 5%(w/v)
higher than the reservoir solution of the crystal. Crystals were soaked
for 2 3 min in cryoprotectants prior to vitrification in liquid nitrogen.
To reduce the cracking of the crystals when immersed directly in the
cryosolution, the cryosolution was first added directly to the crys
tallization drop. After 1 2 min soaking in this solution, the crystals
were then moved with a loop into fresh cryosolution prior to vitrifi
cation in liquid nitrogen. Owing to variation in the diffraction quality,
crystals were first screened on our in house X ray diffraction facilities
at The Hospital for Sick Children (Cu K X ray radiation from an
RU H3R rotating anode generator with R AXIS IV++ image plate
detector) prior to shipment to the National Synchrotron Light Source
(NSLS). A complete set of data was collected at Station X29 at NSLS
at 100 K. A 0.16 mm collimator was used to collect a total of 450
images of 1 ’ oscillations on an ADSCQuantum 315 detector with
a 240 mm crystal to detector distance and an exposure time of 0.5 s
per image. The data were integrated, reduced and scaled using HKL
2000 v.0.95 (Otwinowski & Minor, 1997).
3. Results
The periplasmic protein AlgX from P. aeruginosa has been expressed
and purified to near homogeneity (98%; Fig. 1). Approximately 8 mg
of purified AlgX His6 could be routinely obtained per litre of cell
culture. Diffraction quality crystals have been grown and optimized
with successive rounds of seeding. The crystals diffracted to 2.1 A˚
resolution with no significant evidence of radiation decay over the
collected images. The crystals belonged to space group P21, with unit
cell parameters a 46.4, b 120.6, c 86.9 A˚,  95.7. Data
collection statistics are summarized in Table 1. On the basis of density
calculations (Matthews, 1968), each asymmetric unit is predicted to
contain two monomers of AlgX (VM 2.25 A˚
3 Da1). We are
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Figure 2
Crystals of AlgX. (a) Crystals of the AlgX protein from the initial crystallization
hit; the average dimensions are 50  20  20 mm. (b) Crystals of AlgX following
optimization and successive rounds of seeding. The crystal dimensions are
approximately 200  100  100 mm.
Table 1
Data-collection statistics.
Values in parentheses are for the highest resolution shell.
Wavelength (A˚) 1.0
Temperature (K) 100
Space group P21
Unit-cell parameters (A˚, ) a 46.4, b 120.6,
c 86.9,  95.7
Resolution (A˚) 50–2.1 (2.18–2.10)
Total No. of reflections 334105 (26390)
No. of unique reflections 53287 (5075)
Redundancy 6.27 (5.20)
Completeness (%) 97.2 (95.7)
Average I/(I) 13.9 (2.70)
Rmerge† (%) 11.1 (55.1)
† Rmerge
P
hkl
P
i jIiðhklÞ hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) and hI(hkl)i
represent the diffraction-intensity values of the individual measurements and the
corresponding mean values, respectively.
currently in the process of determining the structure of this protein
using selenomethionine incorporation and the anomalous diffraction
technique (Hendrickson, 1991).
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